Diuretic effect and renal function impact of dapagliflozin in hospitalized patients with HFrEF.
10.11817/j.issn.1672-7347.2024.240294
- Author:
Shanshan LI
1
,
2
;
Youxuan WU
1
;
Xiaolei HU
1
;
Xiaoxiao MAO
3
;
Huijun LIU
3
;
Dai LI
1
;
Pingsheng XU
1
;
Ke XIA
4
Author Information
1. Phase I Clinical Trial Research Center, Xiangya Hospital, Central South University, Changsha
2. 228112398@csu.edu.cn.
3. Department of Cardiovascular Diseases, Xiangya Hospital, Central South University, Changsha 410008, China.
4. Department of Cardiovascular Diseases, Xiangya Hospital, Central South University, Changsha 410008, China. doctorkexia@csu.edu.cn.
- Publication Type:Journal Article
- Keywords:
cost-effectiveness ratio;
dapagliflozin;
diuresis;
heart failure with reduced ejection fraction;
renal function
- MeSH:
Humans;
Benzhydryl Compounds/pharmacology*;
Glucosides/pharmacology*;
Retrospective Studies;
Male;
Female;
Heart Failure/physiopathology*;
Hospitalization;
Middle Aged;
Aged;
Glomerular Filtration Rate/drug effects*;
Diuretics/therapeutic use*;
Kidney/drug effects*;
Natriuretic Peptide, Brain/blood*;
Stroke Volume;
Peptide Fragments/blood*;
Diuresis/drug effects*
- From:
Journal of Central South University(Medical Sciences)
2024;49(11):1732-1740
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:Patients with heart failure with reduced ejection fraction (HFrEF) often require diuretics during hospitalization to alleviate fluid retention and improve prognosis. However, the diuretic efficacy and renal impact of dapagliflozin in this population remain unclear. This study aims to investigate the effects of dapagliflozin on diuresis and renal function in hospitalized patients with HFrEF.
METHODS:This retrospective analysis included clinical data from 200 hospitalized HFrEF patients treated at Xiangya Hospital of Central South University between January 2021 and September 2022. Patients were divided into 2 groups based on whether they received dapagliflozin: a standard treatment group (n=120) and a dapagliflozin treatment group (n=80). The following were compared between the 2 groups during hospitalization: The 24-hour average difference of liquid intake and output during the first 5 days, urine output, cumulative urine output, diuretic efficiency, estimated glomerular filtration rate (eGFR), N-terminal pro B-type natriuretic peptide (NT-proBNP), hospitalization costs, drug costs, and cost-effectiveness ratio (C/E).
RESULTS:1) Primary outcome: The 24-hour average difference of liquid intake and output during the first 5 days was significantly higher in the dapagliflozin treatment group than in the standard treatment group (P<0.05). 2) Secondary outcomes: The 24-hour average urine volume, cumulative urine volume and diuretic efficiency in the first 5 days of dapagliflozin treatment group were higher than those in the standard treatment group, and the differences were statistically significant (all P<0.05). Among patients with impaired renal function on admission [eGFR between 45 and 90 mL/(min·1.73 m²)], the change in eGFR after treatment was significantly smaller in the dapagliflozin treatment group (P<0.05). For patients with normal renal function on admission [eGFR >90 mL/(min·1.73 m²)], the difference in eGFR changes between 2 groups was not significant (P>0.05). NT-proBNP decreased more in the dapagliflozin treatment group than in the standard treatment group during hospitalization (P<0.05). 3) Other indicators: The length of hospital stay was longer in the dapagliflozin treatment group. However, discharge systolic blood pressure, drug costs, and hospitalization costs were all higher in the standard group, though differences were not statistically significant (all P>0.05). The C/E was more favorable in the dapagliflozin treatment group (425.36 vs. 476.67).
CONCLUSIONS:In hospitalized patients with chronic HFrEF, dapagliflozin treatment increased 24-hour average difference of liquid intake and output and total urine output, reduced NT-proBNP levels, and showed a milder decline in eGFR in those with pre-existing renal impairment. Discharge blood pressure, drug costs, and hospital stay were not significantly affected. While standard therapy may offer better short-term clinical benefits, dapagliflozin demonstrated a superior short-term cost-effectiveness profile.
